Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.

Outcomes after CART cell therapy in myeloma is not well known in the literature and the question of whether subsequent immune engager therapies (IET) are efficacious due to T cell exhaustion also remain. Hence, we examined the outcomes of patients post ide-cel, and characterized relapses, therapies, and Progression free survival (PFS) PFS-1, PFS-2 in a real-world setting.Methods: This was a retrospective multicenter observational study of patients who underwent treatment for relapsed Multiple myeloma (MM) with ide-cel from 11 US medical centers.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Murali Janakiram, Jack Khouri, Omar Castaneda, Leyla Shune, Danai Dima, Gurbakhash Kaur, Gabe De Avila, Mahmoud Gaballa, Shonali Midha, James Davis, Charlotte Wagner, Joseph P McGuirk, Peter Forsberg, Ran Reshef, Yi Lin, Aimaz Afrough, Larry D. Anderson, Tags: 39 Source Type: research